Hangzhou Taikun Equity Investment Fund Partnership

Hangzhou Taikun Equity Investment Fund Partnership is a prominent healthcare-focused investment vehicle based in China, established through a strategic partnership between Hangzhou Tigermed Consulting and the Hangzhou municipal government. With a total capital commitment of approximately 20 billion RMB, the fund targets innovative biotechnology, medical devices, and healthcare services globally. The fund utilizes Tigermed's extensive clinical research organization (CRO) infrastructure to provide value-added services and strategic guidance to its portfolio companies. Its investment strategy covers the entire lifecycle of healthcare companies, from early-stage R&D to late-stage growth and commercialization. By fostering innovation in the Hangzhou Biopharma Valley and beyond, the fund aims to accelerate the development of novel therapies and medical technologies.